YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Transaction will add AQNEURSA® (levacetylleucine) to Shionogi's expanding rare disease portfolio AQNEURSA was approved in the United States in 2024 and the European Union in 2026 for neurological manifestations of Niemann-Pick disease type…
Asian stock markets gained ground Monday, after the soft US jobs report on Friday decreased the outl PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Shionogi & Co., Ltd. and Teikoku Ventures, Inc. Join the Round to Accelerate U.S. Clinical Trial Preparations for CLD-001 TOKYO, Oct. 4, 2026 /PRNewswire/ -- Celaid Therapeutics Inc. (Head Office: Bunkyo-ku, Tokyo, Japan; President and CEO…
This article first appeared on GuruFocus. A Deep Dive into the Upcoming Payout and Long-Term Sustainability of Shionogi & Co Ltd Shionogi & Co Ltd (SGIOF) recently announced a total dividend of $0.24 per share, with the ex-dividend date se…
Highlights Include an Oral Presentation of New Data from the Global Phase 3 SCORPIO-PEP Study and New Real-World Analysis on Respiratory Tract Infections from the PROVE Observational Study FLORHAM PARK, N.J., September 09, 2026--(BUSINESS…
OSAKA, Japan, August 28, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced that the Biomedical Advanced Research and Development Authorit…
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.16 per share a year ago. These figures are adjusted…
To date, over 17,300 patients have been treated with RADICAVA ORS® since its availability in June 20221 FLORHAM PARK, N.J., July 30, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Tesh…
Superiority data from LATA, together with OPERA findings, add to the clinical and real-world evidence base for long-acting injectable Cabenuva Six-month follow-up CLARITY data further reinforce a more favourable injection experience with l…
The market expects United Therapeutics (UTHR) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important in assessing the co…
VOGUE is the first head-to-head, randomised daily orals study comparing 2-drug regimen Dovato with 3-drug regimen Biktarvy in treatment-naïve adults living with HIV Real-world OPERA data continues to strengthen the evidence base for Cabenu…
The market expects Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2026. This widely-known consensus outlook is important i…
Submission intends to address a critical therapeutic gap for vulnerable young patients facing drug-resistant pathogens FLORHAM PARK, N.J., July 16, 2026--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd.…
Verrica Pharmaceuticals Inc. – Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese patient in this trial evaluating YCANTH (TO-208) in Japan – – Verrica maintains ownership of global rights to YCAN…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Shionogi (TSE:4507) has just received U.S. FDA approval for XOCOVA…
Cover of the June 2026 issue of Crystal Growth & Design, featuring this research. - Joint Research Involving Rigaku Published in Crystal Growth & Design - TOKYO, June 09, 2026--(BUSINESS WIRE)--Rigaku Corporation, a global solution partner…
XOCOVA® logoXOCOVA® carton packagingXOCOVA® blister packXOCOVA® carton and blister pack combinedShionogi Inc. building exterior Approval is based on SCORPIO-PEP, the only Phase 3 study of an oral antiviral to meet the primary endpoint of p…
TV personality Michelle Visage lends her voice to raise awareness about important differences in long-acting injectable PrEP options More information and resources for people who could benefit from PrEP are available at GetPrEPWisdom.com D…
SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing symptomatic COVID-19 following exposure to an infected individual* Ensitrelvir is an investigational oral antiviral that could…
Akebia Therapeutics (AKBA) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.01. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring item…
D-Wave Quantum (QBTS) president and CEO Alan Baratz sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss Nvidia's (NVDA) artificial intelligence (AI) models for quantum computing, the future of the industry, and more. Video…
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Shionogi has received a major U.S. government contract to manufactu…
DURHAM, N.C., April 10, 2026--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today released "Still Here," a social media video campaign designed to spark crucial c…
Program Includes Establishing Pharmaceutical Manufacturing in the U.S., Procurement and Development of Treatment for Infections Caused by Biothreat Pathogens OSAKA, Japan, April 08, 2026--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office:…
Real-world evidence study carried out in Spain demonstrates 68% clinical cure rate at day 14, and 83% overall survival at day 28, for patients infected with highly resistant metallo-beta lactamase (MBL)-producing pathogens1 Carbapenem-resi…
Tanabe Pharma America Remains Focused on Rare Disease Innovation and Addressing Unmet Patient Needs JERSEY CITY, N.J., April 1, 2026 /PRNewswire/ -- Tanabe Pharma America, Inc. (TPA), the wholly owned subsidiary of Tanabe Pharma Corporatio…
Integration Fully Operational on Day One to Ensure Continuity of Care for the ALS Community With More than 100 Team Members Joining Shionogi from Tanabe Pharma America Acquisition Establishes a Strong Commercial Platform in Rare Disease to…
(RTTNews) - GSK plc (GSK, GSK.L), and Shionogi & Co. announced the completion of the transaction for the 11.7% economic interest in ViiV Healthcare previously held by Pfizer (PFE) to be replaced with an investment by Shionogi (4507.T). Shi…
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Shionogi (TSE:4507) has caught investor attention after a strong past 3 months for the share price, prompting a closer look…
Investors interested in Medical - Drugs stocks are likely familiar with Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their bu…
Transaction strengthens Apnimed's balance sheet as the Company separately prepares to submit its NDA for AD109 in Obstructive Sleep Apnea, expected in the second quarter of 2026 Apnimed retains exclusive rights to AD109 CAMBRIDGE, Mass., M…
BioVersys Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, March 18, 2026 (GLOBE NEWSWIRE) -- Significant clinical and regulatory progress across entire pipeline BV100: Initiated global registrational Phase 3 (RIV-TARGET) in…
VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegra…
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a be…
There are four main publicly-traded quantum computing companies, and they all have one thing in common: In the last 14 months, all of them have been the target of activist investors shorting their stock. This isn’t totally surprising. All…
First-in-human data for long-acting formulations of VH184, the first third-generation integrase inhibitor, and early data for capsid inhibitor VH499 to be presented, highlighting progress in ViiV’s ultra long-acting pipeline 12-month data…